204 related articles for article (PubMed ID: 33172871)
1. Circulating miR-146a expression predicts early treatment response to imatinib in adult chronic myeloid leukemia.
Habib EM; Nosiar NA; Eid MA; Taha AM; Sherief DE; Hassan AE; Abdel Ghafar MT
J Investig Med; 2021 Feb; 69(2):333-337. PubMed ID: 33172871
[TBL] [Abstract][Full Text] [Related]
2. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
3. MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
Yap E; Norziha ZA; Simbun A; Tumian NR; Cheong SK; Leong CF; Wong CL
Leuk Res; 2017 Aug; 59():32-40. PubMed ID: 28544907
[TBL] [Abstract][Full Text] [Related]
4. MiR-150 Expression in Chronic Myeloid Leukemia: Relation to Imatinib Response.
Habib EM; Nosiar NA; Eid MA; Taha AM; Sherief DE; Hassan AE; Abdel Ghafar MT
Lab Med; 2022 Jan; 53(1):58-64. PubMed ID: 34350970
[TBL] [Abstract][Full Text] [Related]
5. Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.
Merx K; Müller MC; Kreil S; Lahaye T; Paschka P; Schoch C; Weisser A; Kuhn C; Berger U; Gschaidmeier H; Hehlmann R; Hochhaus A
Leukemia; 2002 Sep; 16(9):1579-83. PubMed ID: 12200666
[TBL] [Abstract][Full Text] [Related]
6. Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.
Elias MH; Azlan H; Sulong S; Baba AA; Ankathil R
Cancer Rep (Hoboken); 2018 Aug; 1(2):e1111. PubMed ID: 32721103
[TBL] [Abstract][Full Text] [Related]
7. Presence of novel compound BCR-ABL mutations in late chronic and advanced phase imatinib sensitive CML patients indicates their possible role in CML progression.
Akram AM; Iqbal Z; Akhtar T; Khalid AM; Sabar MF; Qazi MH; Aziz Z; Sajid N; Aleem A; Rasool M; Asif M; Aloraibi S; Aljamaan K; Iqbal M
Cancer Biol Ther; 2017 Apr; 18(4):214-221. PubMed ID: 28278078
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
9. MiR-30e induces apoptosis and sensitizes K562 cells to imatinib treatment via regulation of the BCR-ABL protein.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 Jan; 356(2 Pt B):597-605. PubMed ID: 25305453
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
11. [The prognostic value of early BCR-ABL transcripts level in 251 patients with chronic myeloid leukemia after treatment with imatinib].
Bao X; Qiu H; Chen S; Ma X; Tang X; Fu C; Sun A; Wu D
Zhonghua Xue Ye Xue Za Zhi; 2015 Jul; 36(7):553-8. PubMed ID: 26304076
[TBL] [Abstract][Full Text] [Related]
12. Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia.
Flamant S; Ritchie W; Guilhot J; Holst J; Bonnet ML; Chomel JC; Guilhot F; Turhan AG; Rasko JE
Haematologica; 2010 Aug; 95(8):1325-33. PubMed ID: 20460641
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
Lin TY; Chen KC; Liu HJ; Liu AJ; Wang KL; Shih CM
PLoS One; 2016; 11(5):e0156260. PubMed ID: 27228340
[TBL] [Abstract][Full Text] [Related]
14. New strategies in controlling drug resistance in chronic myeloid leukemia.
Frame D
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S16-21. PubMed ID: 18056927
[TBL] [Abstract][Full Text] [Related]
15. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
[TBL] [Abstract][Full Text] [Related]
16. Global identification of circular RNAs in imatinib (IM) resistance of chronic myeloid leukemia (CML) by modulating signaling pathways of circ_0080145/miR-203/ABL1 and circ 0051886/miR-637/ABL1.
Lu YH; Huang ZY
Mol Med; 2021 Nov; 27(1):148. PubMed ID: 34781898
[TBL] [Abstract][Full Text] [Related]
17. p19
Kuang Y; Han X; Cao P; Xiong D; Peng Y; Liu Z; Xu Z; Liang L; Roy M; Liu J; Nie L; Zhang J
Blood Cells Mol Dis; 2020 Nov; 85():102477. PubMed ID: 32711219
[TBL] [Abstract][Full Text] [Related]
18. Expression of inducible NOS is indispensable for the antiproliferative and proapoptotic effect of imatinib in BCR-ABL positive cells.
Singh AK; Awasthi D; Dubey M; Nagarkoti S; Chandra T; Barthwal MK; Tripathi AK; Dikshit M
J Leukoc Biol; 2021 Nov; 110(5):853-866. PubMed ID: 33527482
[TBL] [Abstract][Full Text] [Related]
19. Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia.
Wang L; Pearson K; Pillitteri L; Ferguson JE; Clark RE
Br J Haematol; 2002 Sep; 118(3):771-7. PubMed ID: 12181044
[TBL] [Abstract][Full Text] [Related]
20. Alterations in Sialylation Patterns are Significantly Associated with Imatinib Mesylate Resistance in Chronic Myeloid Leukemia.
Patel KD; De M; Jethva DD; Rathod BS; Patel PS
Arch Med Res; 2022 Jan; 53(1):51-58. PubMed ID: 34275666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
